BDT 001
Alternative Names: BDT-001Latest Information Update: 20 Jan 2023
At a glance
- Originator Biodol Therapeutics
- Class Analgesics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neuropathic pain
Most Recent Events
- 05 Dec 2022 BDT 001 is available for licensing as of 05 Dec 2022. https://www.biodol.eu/#anchor7 (Biodol Therapeutics website, December 2022)
- 05 Dec 2022 Biodol Therapeutics has patent protection for FLT3 inhibitors in the US and European Union (Biodol Therapeutics website, December 2022)
- 31 Aug 2022 Biodol Therapeutics plans to initiate phase I trial in Neuropathic pain in the second half of 2023